Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 1997

View Archived Issues

NCI study indicates potential teratogenicity of AZT

Abbott isolates fusacandin antifungal agents

Daikin synthesizes new ganglioside compounds

New ACAT inhibitors claimed by DuPont Merck

Heterocyclic MDR inhibitors reported by Pfizer

Mayo Foundation reports new natriuretic peptide

Anti-IL-2 monoclonal antibody described by Ajinomoto

More antiobesity proteins in the pipeline at Lilly

cAMP PDE inhibitors disclosed by Nippon Kayaku

Aquila adjuvant shows promise as component of malaria vaccine

New wound-healing agents reported

New amylin antagonists from Amylin

Faulding expands into Europe

Phase II trials begin on ICOS MS treatment

EntreMed licenses dual cytotoxic/antiangiogenic compound

Troglitazone price-listed in Japan

JT to launch new imaging agent soon in Japan

Takeda claims new approach to diabetes Rx

Triangle reports preliminary clinical results with anti-HIV compound

Mochida claims new formulation for ulinastatin

IVAX and Knoll modify European alliance

Adeza obtains clearance for supplementary PMA

Forbes files for U.S. patent related to membrane deficiencies

Zeneca's right to sell prostate cancer drug upheld

Medtronic's arrhythmia management device enters clinic

Olopatadine studied for allergic conjunctivitis

BMS antidepressant chosen for important multiinstitutional trial

Ibopamine efficacy in patients with chronic progressive renal failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...